← Back to Search

Sleep Disturbance Analysis for Gastrointestinal Cancer

N/A
Waitlist Available
Led By Sriram Yennu
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with an expected hospital stay of at least 72 hours
Adult GI Cancer patients admitted for elective gastrointestinal surgery
Must not have
<18 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is designed to determine sleep disturbance and its types among patients with gastrointestinal cancers during the perioperative period by using the Richard Campbell sleep questionnaire.

Who is the study for?
This trial is for adult patients with gastrointestinal cancers who are scheduled for elective surgery and will be in the hospital for at least 3 days. Participants must be able to read and speak English and have internet access or a mobile device compatible with FitBit.
What is being tested?
The study aims to measure sleep disturbances in GI cancer patients during their hospital stay using the Richard Campbell Sleep Questionnaire. Patients will complete this survey daily before and after surgery to assess changes in their sleep quality.
What are the potential side effects?
Since this trial involves completing questionnaires rather than testing a drug, there are no direct side effects from interventions. However, participants may experience discomfort or stress related to reflecting on their sleep patterns.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I will be in the hospital for at least 3 days.
Select...
I am an adult with GI cancer scheduled for elective GI surgery.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am under 18 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Correlating the sleep disturbance and its types among patients with gastrointestinal cancers.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Sleep DisturbancesExperimental Treatment1 Intervention
Difficulty Sleeping

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,070 Previous Clinical Trials
1,802,608 Total Patients Enrolled
American Cancer Society, Inc.OTHER
231 Previous Clinical Trials
109,511 Total Patients Enrolled
Sriram YennuPrincipal InvestigatorM.D. Anderson Cancer Center
12 Previous Clinical Trials
1,357 Total Patients Enrolled

Media Library

Sleep Disturbances Clinical Trial Eligibility Overview. Trial Name: NCT05044312 — N/A
Gastrointestinal Cancer Research Study Groups: Sleep Disturbances
Gastrointestinal Cancer Clinical Trial 2023: Sleep Disturbances Highlights & Side Effects. Trial Name: NCT05044312 — N/A
Sleep Disturbances 2023 Treatment Timeline for Medical Study. Trial Name: NCT05044312 — N/A
~133 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top